Hemostemix (CVE:HEM) Stock Price Up 34.5% – What’s Next?

Hemostemix Inc. (CVE:HEM) traded up 34.5% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. 825,700 shares were traded during trading, an increase of 75% from the average session volume of 472,417 shares. The stock had previously closed at C$0.15.

Hemostemix Stock Up 20.0 %

The business’s fifty day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.07. The company has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.